←
Mike Foote881 posts
Mike Foote avatar

Mike Foote

@MikeFooteMD

GI medical oncologist @MSKCancerCenter | Translational Scientist in @ldiaz1971 lab

◷ Joined June 2010▧ 39 Photos and videos
Mike Foote avatar
Mike Foote@MikeFooteMD·27 Apr 2025

New in @NEJM and #AACR2025: Our Early-stage MMR-d neoadj I/O trial (led by @AndreaCercek & Luis Diaz) •100 % cCR in 49 rectal pts •65 % cCR across 10 other cancers (n=54) •Safe + all non-CR/recurs salvaged. =Use IO in NA for MMR-d tumors! nejm.org/doi/full/10.1056/NE…

Karuna Ganesh avatar
⟳ Mike Foote retweeted
Karuna Ganesh@KarunaMDPhD·May 26

We are thrilled to share our latest work out today @Dev_Cell! Appendiceal adenocarcinoma (AC) is a rare, aggressive cancer that frequently spreads to the peritoneum. Until now, lack of robust preclinical models has severely limited drug discovery. cell.com/developmental-cell/…🧵👇 🔗

Nicholas Hornstein avatar
⟳ Mike Foote retweeted
Nicholas Hornstein@GIMedOnc·4 Nov 2025

Big day for a rare disease 🎉🧬 The new NCCN Guidelines for Appendiceal Cancer just dropped — and they’re fantastic. For the first time, this rare and often misunderstood disease finally gets its own dedicated guidance, instead of the old “just follow colorectal cancer” footnote. 📘 Clear frameworks for diagnosis, staging, and management 🔍 Recognition that appendiceal primaries are biologically distinct 💡 Emphasis on multidisciplinary care and the need for more trials Only downside? @jpshen_md and Michael Foote — two of the biggest names in this space — weren’t listed as contributors. Still, a huge step forward for patients and clinicians who’ve long been navigating in the dark. The field is finally getting the structure it deserves. nccn.org/professionals/physi… @OncoAlert @TheGutOncLab #GIOncology #AppendicealCancer @acpmpresearch

Dra. María Natalia Gandur Quiroga avatar
⟳ Mike Foote retweeted
Dra. María Natalia Gandur Quiroga@nataliagandur·13 Jul 2025

🌟Therapeutic Targeting of MMR-Deficient Cancers🌟 🖋️ Paul Johannet, Benoit Rousseau, Carol Aghajanian, @MikeFooteMD @MSKCancerCenter @ldiaz1971 @NatureRevCancer @Nature @OncoAlert “MMRd tumors: an immunogenic paradox — vulnerable yet resilient” 🔵 Immune-checkpoint inhibitors (ICIs) provide durable responses in many MMRd/MSI-H tumors, regardless of tumor origin 🔵 These tumors harbor frameshift mutations → neoantigens → high immunogenicity 🔵 Strong TILs, checkpoint expression & molecular profile contribute to ICI sensitivity 🔵 Yet, not all MMRd tumors respond and many acquire resistance 🔵 Review explores biology, genomic sequelae, epidemiology & therapeutic strategies 🔵 Highlights emerging biomarkers, resistance mechanisms & future directions 💡 A must-read synthesis connecting tumor genomics with immunotherapy impact #MSI #MMRd #Immunotherapy #ICIs #CancerBiomarkers #OncoImmunology #TumorMicroenvironment #DNARepair #Oncology #CancerResearch #OncoTwitter nature.com/articles/s41571-0…

Post attachmentPost attachmentPost attachmentPost attachment
Mike Foote avatar
Mike Foote@MikeFooteMD·25 Jun 2025

Very excited about our work with 60+ collaborators across the world to define algorithms for management of patients with peritoneal disease! acsjournals.onlinelibrary.wi…

Part 1: Consensus guideline for the management of patients with appendiceal tumors: Appendiceal tumors without peritoneal involvement - Godfrey - 2025 - Cancer - Wiley Online Library acsjournals.onlinelibrary.wi… @DeepaMagge @kturaga @ArdamanShergil1 @MikeFooteMD @JournalCancer @appendix #cancer #raretumors

Post attachment
Mike Foote avatar
Mike Foote@MikeFooteMD·12 Jun 2025

So excited for Benoit Rousseau’s paper in Cancer Cell describing mutagenic chemo combinations to make cold tumors hot! cell.com/cancer-cell/abstrac…

Memorial Sloan Kettering Cancer Center avatar
⟳ Mike Foote retweeted
Memorial Sloan Kettering Cancer Center@MSKCancerCenter·1 Jun 2025

🚨 New research from @ASCO: A clinical trial led by @YJanjigianMD, Chief of Gastrointestinal Medical Oncology at MSK, has demonstrated a powerful new approach to help prevent cancer from coming back after treatment for #stomachcancer and #cancer of the lower portion of the #esophagus and gastroesophageal junction (#GEJ). “For gastroesophageal cancer patients to go through surgery and chemo, it’s devastating to have a recurrence of the cancer,” says Dr. Janjigian. “This trial shows that adding immunotherapy to chemo before and after surgery can dramatically improve the chance that cancer won’t return.” Learn more about how these results offer new hope to people facing this diagnosis, which is the fifth most common cancer worldwide: bit.ly/45Cxpcu #ASCO25

Post attachment
Andrea Cercek avatar
⟳ Mike Foote retweeted
Andrea Cercek@AndreaCercek·29 Apr 2025

Congratulations to our team. Next chapter in Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Journal of Medicine nejm.org/doi/10.1056/NEJMoa2…

Luis Diaz avatar
⟳ Mike Foote retweeted
Luis Diaz@ldiaz1971·28 Apr 2025

New paper from our team at @MSKCancerCenter. Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Journal of Medicine nejm.org/doi/10.1056/NEJMoa2…